NCT02547948

CD19-targeting CAR T Cells for B Cell Lymphoma

CD19-targeting CAR T Cells for Refractory B Cell Lymphoma

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of CD19-targeting CAR T Cells infusion for B Cell Lymphoma.

Detailed description

Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell lymphoma or leukemia. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and CD28. Autologous T cells will be gene-engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.

Conditions

• B Cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CD19-targeting CAR T Cells infusion	CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma

Timeline

• Start date: 2015-09-01
• Primary completion: 2016-08-15
• Completion: 2016-08-15
• First posted: 2015-09-14
• Last updated: 2020-07-16

Locations

1 site across 1 country: China